Shares of Catalyst Pharmaceuticals CPRX gained 16.7% on Wednesday after the company, along with its licensor, SERB, announced that it has entered into a settlement agreement with Teva Pharmaceuticals ...

What Tools Were Used in the Studies for Lambert-Eaton Myasthenic Syndrome (LEMS)? Before describing how Firdapse was studied, it is important to understand the tools that were used in the studies.

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation ...

Catalyst Pharmaceuticals, Inc. CPRX announced positive top-line results from a second phase III study of Firdapse. As the lead pipeline candidate of the company, Firdapse is being developed for the ...

We issued an updated research report on Catalyst Pharmaceuticals Inc. CPRX on Sep 7, 2020. Catalyst’s share price has declined 17.9% compared with the industry’s decline of 9% in the year so far. The ...

Catalyst Pharmaceuticals, Inc.’s CPRX lead drug, Firdapse (amifampridine), is approved in the United States and Europe for the treatment of adult patients with Lambert-Eaton myasthenic syndrome (“LEMS ...

Shares of Catalyst Pharmaceuticals, Inc. CPRX have rallied 25.3% in the past three months compared with the industry’s rise of 2.5%. Zacks Investment Research Image Source: Zacks Investment Research ...

Catalyst Pharmaceuticals CPRX, along with its licensor, SERB, recently announced entering into a settlement agreement with Lupin Pharmaceuticals regarding the Firdapse (amifampridine)patent litigation ...

Catalyst Pharmaceuticals, Inc. CPRX announced the initiation of phase II proof-of-concept study determining the safety, tolerability and efficacy of its lead pipeline candidate, Firdapse ...